Ke Yu

keryu@fudan.edu.cn

English, Chinese

Shanghai

Fudan University

Pharmaceutical Sciences

• 1982/10-1988/03 PhD in Molecular Genetics and Cell Biology: University of Chicago
• 1982/01-1982/09 Graduate Studies in Genetics: Fudan University
• 1978/03-1982/01 Bachelor's in Biology: Shanghai Normal University

• 2011/03-Present - Fudan University - Researcher
• 2010/04-2010/12 - Sandia Biotechnology Company - Deputy General Manager
• 1996/07-2010/03 - Wyeth Pharmaceuticals - Senior Principal Scientist
• 1992/09-1996/06 - Novartis Pharmaceuticals - Associate Scientist
• 1991/04-1992/08 - Cornell University Medical College - Postdoctoral Researcher
• 1988/03-1990/10 - Massachusetts Institute of Technology - Postdoctoral Researcher

• 2015: Major Technology Transfer of SCC-31 (IND 2015)
• 2008: Wyeth Research Institute New Drug PKI-587 Development Award
• 2008: American Chemical Society Industrial Innovation Award 'Heroes of Chemistry'
• 2004: Wyeth Research Institute New Drug PWT-458 Development Team Excellence Award

Targeted therapy research for cancer and other diseases, focusing on innovative drug development. Targets include signaling pathway kinases, cell surface receptors, and tumor metabolism regulation mechanisms. Strategies involve small molecule compounds and innovative monoclonal antibody therapeutic drugs.
Discovery and validation of new molecular sites in tumor-related signaling pathways, focusing on functional analysis in disease models and exploratory research on new drug targets.

• Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines, Toral-Barza L, Zhang WG, Huang X, McDonald LA, Salaski EJ, Barbieri LR, Ding WD, Krishnamurthy G, Hu YB, Lucas J, Bernan VS, Cai P, Levin JI, Mansour TS, Gibbons JJ, Abraham RT, Yu K, 2007
• A new pharmacological action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis, Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons J, Yu K, 2008
• Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin, Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A, 2009
• ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines, Zask A, Verheijen JC, Curran K, Kaplan J, Richard DJ, Nowak P, Malwitz DJ, Brooijmans N, Bard J, Svenson K, Lucas J, Toral-Barza L, Zhang WG, Hollander I, Gibbons JJ, Abraham RT, Ayral-Kaloustian S, Mansour TS, Yu K, 2009
• Discovery of Potent and Selective Inhibitors of the Mammalian Target of Rapamycin (mTOR) Kinase, Nowak P, Cole DC, Brooijmans N, Bursavich MG, Curran KJ, Ellingboe JW, Gibbons JJ, Hollander I, Hu Y, Kaplan J, Malwitz DJ, Toral-Barza L, Verheijen JC, Zask A, Zhang WG, Yu K, 2009
• Mammalian Target of Rapamycin: Discovery of Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell Growth, Gibbons JJ, Abraham RT, Yu K, 2009
• Targeting mTOR globally in cancer: Thinking beyond rapamycin, Shor B, Gibbons JJ, Abraham RT, Yu K, 2009
• Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2, Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, Kim SK, Conant R, Curran K, Kaplan J, Verheijen J, Ayral-Kaloustian S, Mansour TS, Abraham RT, Zask A, and Gibbons JJ, 2010
• Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors, Zask A, Kaplan J, Verheijen JC, Richard DJ, Curran K, Brooijmans N, Bennett EM, Toral-Barza L, Hollander I, Ayral-Kaloustian S, Yu K, 2009
• Hybrid Inhibitors of Phosphatidylinositol-3-Kinase (PI3K) and the Mammalian Target of Rapamycin (mTOR): Design, Synthesis, and Superior Antitumor Activity of Novel Wortmannin-Rapamycin Conjugates, Ayral-Kaloustian S, Gu J, Lucas J, Cinque M, Gaydos C, Zask A, Chaudhary I, Wang J, Di L, Young M, Ruppen M, Mansour TS, Gibbons JJ, Yu K, 2010
• Requirement of mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells, Shor B, Wu J, Shakey Q, Toral-Barza L, Follettie M, Yu K, 2010
• Ammonia derived from glutaminolysis is a diffusible regulator of autophagy, Eng C, Yu K, Lucas J, White E, Abraham RT, 2010
• Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor, Yu K and Toral-Barza L, 2012
• A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers, Meng L, Shu M, Chen Y, Yang D, He Q, Zhao H, Feng Z, Liang C, Yu K, 2014